Cancer Prevention with Molecular Target Therapies
Personalized medicine plays an important role in cancer prevention. To date, it is clear that many cancers are molecularly distinct subtypes, and different therapeutic approaches would be required for each. Indeed, the identification of cancer susceptibility genes permits identifying patients “at ri...
Salvato in:
| Natura: | Online |
|---|---|
| Lingua: | inglese |
| Pubblicazione: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Soggetti: | |
| Accesso online: | ONIX_20230714_9783036579276_38 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1869527155512180736 |
|---|---|
| collection | Directory of Open Access Books |
| description | Personalized medicine plays an important role in cancer prevention. To date, it is clear that many cancers are molecularly distinct subtypes, and different therapeutic approaches would be required for each. Indeed, the identification of cancer susceptibility genes permits identifying patients “at risk” of developing neoplasia and supports modifying individual risk behaviors or the choice of preventive therapy. Additionally, the efficacy of various targeted therapies in different cancer subtypes suggests that treatment choices in the near future will be more and more centered on molecular signatures. Data from preclinical, clinical, and observational studies have revealed the ability to prevent cancer development for compounds with different indications than cancer. The concept of drug repurposing permits combinations that can target several critical pathways of a specific disease, decreasing the risk of resistance observed when using single-agent targeted therapy.This open-access Special Issue brings together original research and review articles on molecular oncology with attention to the early detection and prevention of cancer. It highlights new findings, methods, and technical advances in molecular cancer research. The main feature of this Special Issue is to provide an open-source sharing of significant works in the field of molecular oncology that can increase our understanding of cancer development, which may lead to the discovery of new molecular diagnostic technologies and targeted therapeutics. |
| format | Online |
| id | doab-20.500.12854ir-101339 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1013392024-03-31T13:10:44Z Cancer Prevention with Molecular Target Therapies Paleari, Laura melanoma β3-tubulin microtubules microvesicles endometrial cancer steroid receptors aromatase inhibitors progression free survival overall survival ALK EGFR non-small-cell lung cancer (NSCLC) immune checkpoint inhibitor (ICI) adenocarcinoma GANT61 non-canonical Hedgehog-GLI signaling hepatocellular carcinoma tyrosine kinase inhibitor multidrug resistance cancer ABC transporter SLC transporter lysosomal sequestration cancer cell migration prognosis biomarker extracellular vesicles lipid metabolism human thymidylate synthase peptidic-inhibitors pH-sensitive PEGylated liposomes ovarian cancer drug-resistance raltitrexed 5-fluorouracil bladder cancer muscle invasive non-muscle invasive molecular subtypes evolution targeted therapy classification gut microbiota NAFLD HCC dysbiosis metabolites NSCLC early stage osimertinib DMTF1 ARF INK4a p53 Cyclin D1 YY1 STAT3 tumor promoter tumor suppressor thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Personalized medicine plays an important role in cancer prevention. To date, it is clear that many cancers are molecularly distinct subtypes, and different therapeutic approaches would be required for each. Indeed, the identification of cancer susceptibility genes permits identifying patients “at risk” of developing neoplasia and supports modifying individual risk behaviors or the choice of preventive therapy. Additionally, the efficacy of various targeted therapies in different cancer subtypes suggests that treatment choices in the near future will be more and more centered on molecular signatures. Data from preclinical, clinical, and observational studies have revealed the ability to prevent cancer development for compounds with different indications than cancer. The concept of drug repurposing permits combinations that can target several critical pathways of a specific disease, decreasing the risk of resistance observed when using single-agent targeted therapy.This open-access Special Issue brings together original research and review articles on molecular oncology with attention to the early detection and prevention of cancer. It highlights new findings, methods, and technical advances in molecular cancer research. The main feature of this Special Issue is to provide an open-source sharing of significant works in the field of molecular oncology that can increase our understanding of cancer development, which may lead to the discovery of new molecular diagnostic technologies and targeted therapeutics. 2023-07-14T14:25:20Z 2023-07-14T14:25:20Z 2023 book ONIX_20230714_9783036579276_38 9783036579276 9783036579269 https://directory.doabooks.org/handle/20.500.12854/101339 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/7434 https://mdpi.com/books/pdfview/book/7434 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-7926-9 10.3390/books978-3-0365-7926-9 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036579276 9783036579269 208 Basel open access |
| spellingShingle | melanoma β3-tubulin microtubules microvesicles endometrial cancer steroid receptors aromatase inhibitors progression free survival overall survival ALK EGFR non-small-cell lung cancer (NSCLC) immune checkpoint inhibitor (ICI) adenocarcinoma GANT61 non-canonical Hedgehog-GLI signaling hepatocellular carcinoma tyrosine kinase inhibitor multidrug resistance cancer ABC transporter SLC transporter lysosomal sequestration cancer cell migration prognosis biomarker extracellular vesicles lipid metabolism human thymidylate synthase peptidic-inhibitors pH-sensitive PEGylated liposomes ovarian cancer drug-resistance raltitrexed 5-fluorouracil bladder cancer muscle invasive non-muscle invasive molecular subtypes evolution targeted therapy classification gut microbiota NAFLD HCC dysbiosis metabolites NSCLC early stage osimertinib DMTF1 ARF INK4a p53 Cyclin D1 YY1 STAT3 tumor promoter tumor suppressor thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Cancer Prevention with Molecular Target Therapies |
| title | Cancer Prevention with Molecular Target Therapies |
| title_full | Cancer Prevention with Molecular Target Therapies |
| title_fullStr | Cancer Prevention with Molecular Target Therapies |
| title_full_unstemmed | Cancer Prevention with Molecular Target Therapies |
| title_short | Cancer Prevention with Molecular Target Therapies |
| title_sort | cancer prevention with molecular target therapies |
| topic | melanoma β3-tubulin microtubules microvesicles endometrial cancer steroid receptors aromatase inhibitors progression free survival overall survival ALK EGFR non-small-cell lung cancer (NSCLC) immune checkpoint inhibitor (ICI) adenocarcinoma GANT61 non-canonical Hedgehog-GLI signaling hepatocellular carcinoma tyrosine kinase inhibitor multidrug resistance cancer ABC transporter SLC transporter lysosomal sequestration cancer cell migration prognosis biomarker extracellular vesicles lipid metabolism human thymidylate synthase peptidic-inhibitors pH-sensitive PEGylated liposomes ovarian cancer drug-resistance raltitrexed 5-fluorouracil bladder cancer muscle invasive non-muscle invasive molecular subtypes evolution targeted therapy classification gut microbiota NAFLD HCC dysbiosis metabolites NSCLC early stage osimertinib DMTF1 ARF INK4a p53 Cyclin D1 YY1 STAT3 tumor promoter tumor suppressor thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| topic_facet | melanoma β3-tubulin microtubules microvesicles endometrial cancer steroid receptors aromatase inhibitors progression free survival overall survival ALK EGFR non-small-cell lung cancer (NSCLC) immune checkpoint inhibitor (ICI) adenocarcinoma GANT61 non-canonical Hedgehog-GLI signaling hepatocellular carcinoma tyrosine kinase inhibitor multidrug resistance cancer ABC transporter SLC transporter lysosomal sequestration cancer cell migration prognosis biomarker extracellular vesicles lipid metabolism human thymidylate synthase peptidic-inhibitors pH-sensitive PEGylated liposomes ovarian cancer drug-resistance raltitrexed 5-fluorouracil bladder cancer muscle invasive non-muscle invasive molecular subtypes evolution targeted therapy classification gut microbiota NAFLD HCC dysbiosis metabolites NSCLC early stage osimertinib DMTF1 ARF INK4a p53 Cyclin D1 YY1 STAT3 tumor promoter tumor suppressor thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| url | ONIX_20230714_9783036579276_38 |